US cell therapies firm Promethera secures investment from ITOCHU
ITOCHU is the first lead investor in Promethera’s new investment round, which is expected to be completed in the first quarter of this year. The US pharma firm is
Novartis has begun construction on its new 46,000ft² radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking the latest step in its $23bn investment in US manufacturing and research.